Quince Therapeutics sells Italian unit and A-T drug technology to Ayma for $450,000
The September 8, 2026 asset sale offloads Quince's eDSP program and its Italian subsidiary while the company's president departs the same day.
SEC filing
Latest
4 stories
Monday, September 14
Thursday, August 27
Quince Therapeutics discloses departure of President Charles Ryan
The company reported the leadership change in an 8-K with an event date of August 23, 2026, and a signature date of August 27, 2026.
SEC filing
Friday, August 14
Quince Therapeutics reports Q2 2026 results after closing Orphai acquisition
The company folded in Orphai's inhaled rapamycin program LAM-001 and raised $115 million as it advances trials in three pulmonary diseases.
SEC filing
Friday, July 31
Quince CEO Thye and COO Hannah file conditional resignations ahead of Orphai deal vote
The moves are tied to stockholder approval of proposals needed to complete Quince's acquisition of Orphai Therapeutics and related financing.
SEC filing